EPO Biosimilars - The Future of Erythropoietin Market
Erythropoietin is a hormone produced by healthy kidneys. This hormone prompts the bone marrow to make the red blood cells, which then carry oxygen throughout the body. Erythropoietin is used to treat anemia resulting from kidney failure or cancer treatment. It is considered to be an alternative to blood transfusions. Over the last few years, the global erythropoietin industry has been showing a sluggish growth due to patent expiry of biologic drugs. However, the biosimilar versions of these drugs are expected to witness precipitous growth owing to their low cost.
As per RNCOS report “EPO Biosimilars - The Future of Erythropoietin Market”, the global erythropoietin market is anticipated to reach an approximate value of US$ 7 Billion by 2020. This report provides a detailed analysis of the current and future market scenario of the global erythropoietin market. The report highlights biosimilar erythropoietin at various stages of clinical development. In addition, the report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth.
For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/epo-biosimilars-the-future-of-erythropoietin-market
The global erythropoietin market has been segmented into biologic and biosimilar erythropoietin markets. The report also highlights the various biologic and biosimilar erythropoietin drugs currently available in the market. Furthermore, the global erythropoietin market has also been segmented on the basis of their applications. Based on geography, the report divides the market into the US, Europe, and Asia-Pacific.
The last section of the report discusses about the prominent players in global erythropoietin market. Market share analysis of these players is also provided in the report. A brief business overview and financial information about each of these players has been provided along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global erythropoietin market.
To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=36417
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.
Senior Vice President
101, Arch Street
Boston, MA 02110
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release EPO Biosimilars - The Future of Erythropoietin Market here
News-ID: 568760 • Views: …
More Releases from ReportsWorldwide
World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of
More Releases for Erythropoietin
Erythropoietin Market Size, Share, Development by 2023
New report published by Market Research Report Store (MRRS) which offers insights on the global Erythropoietin market. Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Click to view the
Global Erythropoietin Drugs Market: Segmentation
The global erythropoietin drugs market has been projected in a report by Transparency Market Research (TMR) to witness a rising focus on product development adopted by prominent companies operating in the industry. Players could be persuaded to search for new distributors due to the escalating level of competition in the market. For the purpose of earning an improved return of investment (ROI), players have been predicted to set their focus
Erythropoietin Drugs Market
Erythropoietin alfa is widely used to treat anemia and increase the red blood cells count in the body. Erythropoietin drugs are developed in vitro by extracting the erythropoietin from the human body and developing it through the use of recombinant DNA technology. Erythropoietin drugs are also used to treat anemia induced from cancer, multiple myloma and HIV associated anemia. Recombinant DNA technology has allowed researchers to develop synthetic forms of
European Erythropoietin Market Outlook 2022
ReportsWorldwide has announced the addition of a new report title European Erythropoietin Market Outlook 2022 to its growing collection of premium market research reports. Erythropoietin drugs are protein therapeutics, which is used to treat various types of anaemia. These drugs play a significant role in treating CKD related anaemia and cancer related anaemia. Since its inception, the erythropoietin drugs market has witnessed various technological advancements, which have resulted in development of
Global Erythropoietin Market Research Report 2017
This report studies Erythropoietin in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Amgen Johnson & Johnson Roche Galenica Emcure Kyowa Hakko Kirin 3SBio Biocon LG Life Sciences Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Erythropoietin in these regions, from 2011 to
Erythropoietin Drugs Market — Global Industry Insights 2024
Market Overview Erythropoietin alfa is widely used to treat anemia and increase the red blood cells count in the body. Erythropoietin drugs are developed in vitro by extracting the erythropoietin from the human body and developing it through the use of recombinant DNA technology. Erythropoietin drugs are also used to treat anemia induced from cancer, multiple myloma and HIV associated anemia. Recombinant DNA technology has allowed researchers to develop synthetic forms